This is a multicenter, randomized, double-blinded, positive controlled study to evaluate the lot-to-lot consistency, immunogenicity and safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in adults aged 18 to 55 years. Subjects will be randomized to receive investigational Lot 1, Lot 2, Lot 3 vaccine or control vaccine in a 1:1:1:1 ratio, with the subjects in experimental group randomly and equally assigned to three different batches of MCV4 for single-dose vaccination.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The geometric mean titer (GMT) of serogroup A, C, Y and W135 meningococcal rSBA titer in all participants.
Timeframe: Day 30 post vaccination
The seroconversion rate of serogroup A, C, Y, and W135 meningococcal rSBA titer.
Timeframe: Day 30 post vaccination
The incidence of adverse reactions (ARs) in all participants.
Timeframe: Within 7 days post vaccination